Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

From the 12th to the 15th, the JP Morgan Healthcare Conference, widely regarded as the world’s largest pharmaceutical and ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Over the past few years, Axsome Therapeutics has made slow and steady clinical and regulatory progress. The company's lineup ...

Focusing on 2026 as a starting point, PwC has laid out several “strategic imperatives” pharma companies ought to pursue this ...

1) Innovent has positioned itself at the forefront of China’s GLP-1 market with Mazdutide, the first-in-class dual GCG/GLP-1 receptor agonist approved for obesity and overweight in June 2025.

Amgen is committed to reducing drug costs, expanding its AmgenNow program, and investing in US manufacturing to gain tariff ...

As of Friday, January 02, Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 60.00%, which has investors ...

Amgen is getting down with Disco Pharmaceuticals, commissioning the German biotech to work on cancer therapies focused on a ...

IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparatorIM1240's ...

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A ...

In The Star's annual year in review, the county's biggest business stories included housing proposals and the aftermath of a ...